546115-43-9

Basic information

• Product Name: methyl (S)-3-(3-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate
• Synonyms: methyl (S)-3-(3-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate
• CAS NO: 546115-43-9
• Molecular Weight: 358.232
• Mol File: 546115-43-9.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: methyl (S)-3-(3-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (S)-3-(3-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate(546115-43-9)
• EPA Substance Registry System: methyl (S)-3-(3-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate(546115-43-9)

Safety Data

• Hazardous Substances Data: 546115-43-9(Hazardous Substances Data)

Upstream product

• 82278-73-7 (2S)-3-(3-bromophenyl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 900800-04-6 (S)-3-(3-allyl-phenyl)-2-tert-butoxycarbonylamino-propionic acid methyl ester 
• 1240613-04-0 methyl (S)-3-(3-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 1620084-43-6 (S)-methyl 3-(3-allylphenyl)-2-(2-(2-bromo-5-methoxy-1H-pyrrolo[3,2-b]pyridin-3-yl)acetamido)propanoate 
• 1620084-44-7 (S)-tert-butyl 3-(2-(3-(3-allylphenyl)-1-methoxy-1-oxopropan-2-ylamino)-2-oxoethyl)-2-bromo-5-methoxy-1H-pyrrolo[3,2-b]pyridine-1-carboxylate 
• 1240613-03-9 methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate 
• 875782-96-0 C₁₀H₁₂BrNO₂ 

Relevant articles and documents

AZETIDINE DERIVATIVE, AND PRODRUG THEREOF

An object of the present invention is to provide a compound useful as a therapeutic or prophylactic drug for a disease involving the immune system, by suppressing a function of immune cells by suppressing proliferation of activated T cells or suppressing production of interferon alpha (IFN-α) by activated plasmacytoid dendritic cells (pDC), particularly an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis in SLE patients. The present invention provides a compound represented by general formula (I) : [wherein X, R1, R2, R3, R4, R5 and R6 are as described in the description], or a pharmaceutically acceptable salt thereof.

RAS INHIBITORS

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Functionalization of aromatic amino acids via direct C-H activation: Generation of versatile building blocks for accessing novel peptide space

Functionalized α-amino acid building blocks have been prepared in good yield with high regiocontrol and preservation of stereochemistry via iridium-catalyzed borylation of suitably protected aromatic α-amino acid derivatives. The utility of these systems